ASCO26: Sara Tolaney, MD, MPH, ASCENT-04 - Takeaways - MDSpire

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

Share

  • 1

    Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study at ASCO26.

  • 2

    Patients receiving sacituzumab govitecan plus pembro had longer progression-free survival than those on standard therapy.

  • 3

    The analysis indicated potentially meaningful improvements in overall survival with the combination therapy.

  • 4

    The study focused on biomarker-based subgroup analysis.

  • 5

    Strategies to enhance adoption of ePRO-based symptom management may be necessary.

Original Source(s)

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

  • July 1, 2026

Related Content

Case Report: Synchronous minute intramucosal Epstein–Barr virus-associated gastric cancer revealed after short-term Helicobacter pylori eradication

Bladder metastasis from gastric cancer presenting as acute post-renal obstruction during immunotherapy: a case report

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study